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Purpose: To test whether the increased signal-to-noise ratio of 
phosphorus 31 (31P) magnetic resonance (MR) spectros-
copy at 7 T improves precision in cardiac metabolite quan-
tification in patients with dilated cardiomyopathy (DCM) 
compared with that at 3 T.
Materials and 
Methods:
Ethical approval was obtained, and participants provided 
written informe consent. In a prospective study, 31P MR 
spectroscopy was performed at 3 T and 7 T in 25 patients 
with DCM. Ten healthy matched control subjects under-
went 31P MR spectroscopy at 7 T. Paired Student t tests 
were performed to compare results between the 3-T and 
7-T studies.
Results: The phosphocreatine (PCr) signal-to-noise ratio increased 
2.5 times at 7 T compared with that at 3 T. The PCr to 
adenosine triphosphate (ATP) concentration ratio (PCr/
ATP) was similar at both field strengths (mean 6 stan-
dard deviation, 1.48 6 0.44 at 3 T vs 1.54 6 0.39 at 7 T, 
P = .49), as expected. The Cramér-Rao lower bounds in 
PCr concentration (a measure of uncertainty in the mea-
sured ratio) were 45% lower at 7 T than at 3 T, reflecting 
the higher quality of 7-T 31P spectra. Patients with dilated 
cardioyopathy had a significantly lower PCr/ATP than did 
healthy control subjects at 7 T (1.54 6 0.39 vs 1.95 6 
0.25, P = .005), which is consistent with previous findings.
Conclusion: 7-T cardiac 31P MR spectroscopy is feasible in patients 
with DCM and gives higher signal-to-noise ratios and more 
precise quantification of the PCr/ATP than that at 3 T. 
PCr/ATP was significantly lower in patients with DCM 
than in control subjects at 7 T, which is consistent with 
previous findings at lower field strengths.
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method from echocardiographic data. 
In total, 101 patients were considered 
for this study. Patients were excluded if 
they did not wish to participate (22 pa-
tients), if their heart was not beating in 
sinus rhythm (seven patients had atrial 
fibrillation), if they had valvular heart 
disease (five patients), or if they had a 
contraindication to MR imaging at 3 T 
or 7 T (21 for implanted cardiac devices 
or cardiac resynchronization therapy 
implants, 18 for metal from previous 
surgery, and three for tattoos). An-
other exclusion criterion was coronary 
artery disease, but none of the patients 
had it. The exclusion criteria for 3-T 
MR imaging were familiar to the clini-
cal care team already (atrial fibrillation, 
valvular disease, implantable cardio-
verter defibrillators or cardiac resyn-
chronization therapy devices), but 
given the relatively strict screening 
criteria for 7-T MR imaging, approxi-
mately 40% of potential patients who 
completed the laboratory volunteer 
screening form were found to have a 
safety contraindication to MR imaging 
at 7 T. The LV ejection fraction was 
verified from the first study sequence, 
and patients would have been excluded 
Whole-body 7-T imagers capable 
of cardiac MR imaging recently have 
become available, and 31P MR spec-
troscopy has been shown to be feasible 
in healthy volunteers at 7 T (8). We 
hypothesize that these new systems 
can be used in patients with cardiac 
disease and that they will allow an 
improvement in the quality of 31P MR 
spectroscopy, enabling detection of 
small changes in metabolite concen-
trations or studies in small patient 
groups, which will further the under-
standing of cardiac energetics. Imaging 
patients with cardiac disease instead 
of healthy volunteers poses additional 
challenges such as the potential inabil-
ity of the patients to tolerate the length 
of the examination and the physiologic 
monitoring in the magnet bore, and a 
potential reduction in the fraction of 
myocardium within a spectroscopic 
voxel due to the thinning of the ven-
tricular walls in patients with DCM, 
which may challenge our ability to 
correct for blood contamination. This 
study was designed to test whether the 
increased 31P MR spectroscopic SNR 
at a field strength of 7 T improves pre-
cision in cardiac metabolite quantifica-
tion in patients with DCM compared 
with that with imaging at 3 T.
Materials and Methods
Study Cohort
This study was approved by the Soli-
hull ethics committee (REC Ref 13/
WM/0155) and all participants gave 
written informed consent. Patients 
were eligible for inclusion if they had 
a clinical diagnosis of DCM and an LV 
ejection fraction of less than 50%, as 
measured with the Simpson biplane 
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Advances in Knowledge
 n Cardiac 7-T MR spectroscopy is 
feasible and well tolerated in 
patients.
 n The signal-to-noise ratio (SNR) of 
phosphorus spectroscopy in 
patients with dilated cardiomyop-
athy was 2.5 times higher at 7-T 
field strength (phosphocreatine 
SNR = 16.4 6 7.6 at 7 T), com-
pared with spectroscopy at 3-T 
field strength (phosphocreatine 
SNR = 6.5 6 2.4 at 3 T).
 n The Cramér-Rao lower bounds in 
the uncertainty of metabolite 
quantification with phosphorus 
spectroscopy in the human heart 
were 45% lower at 7-T field 
strength compared with those at 
3-T field strength (the percentage 
of phosphocreatine Cramér-Rao 
lower bounds decreased from 
17.5% 6 6.5 at 3 T to 7.1% 6 
3.7 at 7 T in patients with di-
lated cardiomyopathy).
Implication for Patient Care
 n The use of 7-T MR imagers for 
cardiac phosphorus spectroscopy 
allows more precise quantifica-
tion of cardiac metabolites, 
which is an important step 
toward monitoring the metabolic 
state of an individual patient’s 
heart over time.
Heart failure is a global health problem that causes widespread morbidity and mortality (1). 
Heart failure due to dilated cardiomy-
opathy (DCM) is characterized by in-
creased ventricular volume and global 
impairment of systolic function (2). 
Phosphorus 31 (31P) magnetic reso-
nance (MR) spectroscopy provides 
unique insight into cardiac energetics 
in vivo but is a technique with intrin-
sically low signal-to-noise ratio (SNR) 
because of low metabolite concentra-
tions (3); a low gyromagnetic ratio, 
g31P; and relatively long T1 relaxation 
times. These factors lead to undesir-
able variability in human spectra and 
impede single-subject comparisons 
(3–5). 31P MR spectroscopic studies in 
patients with DCM have demonstrated 
derangement of cardiac energetics 
characterized by a reduction in the 
phosphocreatine (PCr) to adenosine 
triphosphate (ATP) concentration ra-
tio (PCr/ATP), which may be superior 
to the New York Heart Association 
functional class or left ventricular (LV) 
ejection fraction for prediction of mor-
tality in patients with DCM (6,7).
Radiology: Volume 281: Number 2—November 2016 n radiology.rsna.org 411
CARDIAC IMAGING: 31P MR Spectroscopy at 7 T in Patients with Dilated Cardiomyopathy Stoll et al
and repetition time, 1 second (8). At 
7 T, excitation was at 400 V (ie, 3.2 
kW), giving a field of approximately 
10 µT in the interventricular septum, 
and hence, a flip angle of approxi-
mately 30° there. At 3 T, flip angles 
were matched to those at 7 T by using 
the subject-specific B1 maps. Excitation 
was centered at −250 Hz at 3 T and at 
more than +266 Hz at 7 T (both rela-
tive to PCr). A 25-mm-thick saturation 
band suppressed the signal from the 
anterior chest wall. At 7 T, this was 
set to the maximum voltage permissi-
ble (equivalent to the maximum power 
permissible) within the radiofrequency 
heating limits for each subject.
Spectra from a voxel overlying the 
midventricular septum were fitted by 
an expert in MR spectroscopy (W.T.C.) 
under the guidance of another ex-
pert in MR spectroscopy (C.T.R.) by 
using a custom Matlab (Mathworks, 
Natick, Mass) implementation of the 
advanced method for accurate, robust, 
and efficient spectroscopic (AMARES) 
fitting (15), with prior knowledge 
specifying 11 Lorentzian peaks (a, b, 
g-ATP, PCr, phosphodiester, and 2 3 
2, 3-diphosphoglycerate), fixed am-
plitude ratios, and literature values 
for the scalar couplings for the multi-
plets. This set of prior knowledge has 
been used successfully in several pre-
vious 31P MR spectroscopic studies 
in Oxford, UK (5). The residual after 
fitting the spectrum typically showed no 
features above the noise level, suggest-
ing that this is an adequate description 
of the spectra. We then corrected for 
blood contamination (16) and partial 
saturation (17) by using T1 values from 
the literature (5,8). The final PCr/ATP 
was taken as PCr/g-ATP by discount-
ing a-ATP, because it overlaps nicotin-
amide adenine dinucleotide phosphate 
(NADPH) and b-ATP because it was 
not fully excited at 7 T and had a phase 
artifact in some subjects at 3 T. Finally, 
the spectral SNR was determined (18), 
and the uncertainty in metabolite con-
centrations was expressed by their Cra-
mér-Rao lower bounds (19); Cramér-
Rao lower bounds give the theoretical 
minimum for a parameter’s 95% confi-
dence limits.
years of experience in 31P MR spectros-
copy, respectively). The 3-T coil was 
chosen because, of the coils available 
in our laboratory, it historically has 
performed best in vivo (3,5,12,13), 
and this was confirmed with phantom 
imaging sequences. (Specifically, at 3 
T, the heart-liver coil has a low drop-
off in transmit performance through-
out the heart [40% drop-off between 
8-cm and 12-cm depth vs 64% for a 
10-cm loop]; it has a good receive SNR 
at the depth of the heart [approxi-
mately 10 cm], measured as 6% better 
than that with an eight-element receive 
array in healthy volunteers [12]; and 
it benefits from a larger head-to-foot 
and left-to-right field of view compared 
with those of smaller loop coils, mak-
ing coil placement less critical than 
with a 10-cm loop [8]). At 7 T, the 
16-element array was chosen because 
phantom imaging showed that it gives 
more uniform transmit performance 
and greater SNR at the depth of the 
heart (approximately 10 cm), as shown 
in figure 2 of reference 11. Participants 
were imaged prone at 3 T (required 
for the coil) and supine at 7 T (for im-
proved comfort). Both sequences were 
performed sequentially on the same 
day to minimize any physiologic vari-
ation. Spectroscopic sequences were 
not gated to avoid potential bias due to 
mistriggering, particularly at 7 T (14). 
(Although we note that recent studies 
in Oxford were not gated at 3 T, and 
not gating avoids the potential for ar-
tifacts from mistriggering, which also 
often occurs during a 28-min sequence 
in patients at 3 T). Control subjects 
underwent 31P MR spectroscopy as de-
scribed at 7 T only, because we already 
have characterized the performance 
of the 3-T heart-liver coil extensively 
(3,5).
As previously described, localiza-
tion was performed and subject-spe-
cific B1 maps were computed (5,8). 
Spectra were recorded by using a 
chemical-shift imaging pulse sequence 
(three-dimensional phase-encoded “ul-
trashort echo time” chemical shift im-
aging) with matrix, 16 3 16 3 8; voxel 
size, 15 3 15 3 25 mm3; acquisition 
weighting with 10 averages (k = 0); 
if they had had an LV ejection fraction 
greater than 50% according to cardiac 
MR imaging, but no patients did. In to-
tal, 25 patients with DCM (mean age 6 
standard deviation, 54 years 6 12, 68% 
men) were enrolled in the study, and 
10 age- and sex-matched healthy con-
trol subjects (mean age, 52 years 6 12, 
80% men) with no history of cardiac 
disease were enrolled for 31P MR spec-
troscopy at 7 T only.
Clinical Measurements
All patients answered the Minne-
sota Heart Failure questionnaire (9), 
which is a quality-of-life score with 21 
questions used to assess heart failure 
symptoms over the preceding 4 weeks, 
with scores ranging from 0 (no effect) 
to 5 (great effect). Height and weight 
were recorded, and body mass index 
was calculated. Blood pressure was re-
corded (Dinamap-1846-SX; Critikon, 
Tampa, Fla). Venous blood was drawn 
for brain-type natriuretic peptide levels. 
Participants underwent a 6-minute walk 
test (10).
31P MR Spectroscopic Protocol
In this study, we compared best-in-class 
3-T methods against our newest 7-T 
hardware and methods to quantify the 
real-world improvement. Each patient 
underwent 31P MR spectroscopic imag-
ing with a 3-T imager (Trio; Siemens, 
Erlangen, Germany) and a heart-liver 
coil (5) and with a 7-T imager (Sie-
mens) and a 16-channel coil (Rapid 
Biomedical, Würzberg, Germany) 
(11). The heart-liver coil comprises a 
28 3 27–cm2 rectangular 31P transmit 
loop (also used for hydrogen 1 [1H] 
transmit and receive) and a loop/but-
terfly quadrature 31P receive pair (12 
3 15−cm loop and 23 3 12−cm but-
terfly) connected through a hardware 
quadrature combiner to a single receive 
channel. The 16-channel coil comprises 
a rigid 26 3 28−cm2 rectangular 31P 
transmit element and a flexible set of 
16 overlapping 4-cm diameter circular 
receive elements in a 4 3 4 grid.
Imaging was performed by two op-
erators (V.S., a clinician with 3 years of 
experience in cardiac MR imaging and 
either C.T.R. or W.T.C., with 8 and 4 
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by using the D’Agostino and Pearson 
omnibus normality tests and were pre-
sented as means 6 standard deviation. 
Two-group comparisons for normally 
distributed data were analyzed by us-
ing the Welch t test, or with the paired 
Student t test, where appropriate, 
while nonnormally distributed data 
were analyzed with the Mann Whitney 
U test. Correlation was assessed with 
the Pearson or Spearman correlation 
coefficient, as appropriate. P values 
before enrollment. To determine mid-
ventricular peak systolic circumfer-
ential strain and diastolic strain rate, 
myocardial tagging was performed 
(21,22) and analyzed by using software 
(CimTag2D; Auckland Medical Re-
search, Auckland, New Zealand) (23).
Statistical Analysis
Statistical analysis was performed 
with software (SPSS; IBM, Chicago, 
Ill). Data were tested for normality 
Additional Cardiac MR Imaging 
Sequences
LV volume stacks were recorded for 
all subjects at 3 T by using a 32-chan-
nel cardiac coil to acquire steady-state 
free precession cine images, which 
were analyzed by using software (Fus-
ing cmr42; Circle Cardiovascular Im-
aging, Calgary, Canada) as previously 
described (20). All patients had an LV 
ejection fraction less than 50%, which 
is consistent with their measurements 
Table 1
Demographic, Clinical, and Imaging Characteristics of Study Participants
Characteristic Healthy Control Subjects (n = 10) Patients with DCM (n = 25) P Value
Demographic parameters
 Age (y) 52 6 12 54 6 12 .646
 No. of men* 8 (80) 17 (68) .686
 Body mass index (kg/m2) 23 6 2 28 6 5 .002
 Systolic blood pressure (mm Hg) 124 6 13 130 6 20 .429
 Diastolic blood pressure (mm Hg) 77 6 9 72 6 13 .296
 Heart rate (beats per min) 64 6 12 62 6 13 .660
 Minnesota Heart Failure Questionnaire score . . . 19 6 17 . . .
 6-minute walk test (m) 634 6 89 509 6 80 ,.0001
 Brain-type natriuretic peptide (pmol/L) 5.3 6 2.4 33.5 6 43.8 .006
 Method used to determine absence of coronary artery disease*
  Angiographic results normal . . . 13 (52) . . .
  Negative perfusion sequence at nuclear or MR imaging . . . 7 (28) . . .
  Coronary CT results normal . . . 1 (4) . . .
  Age , 35 and no risk factors† . . . 4 (16) . . .
No. of patients taking medications*
 b-Blockers . . . 18 (72) . . .
 Angiotensin-converting enzyme inhibitors/angiotensin II  
  receptor blockers
. . . 23 (92) . . .
 Diuretics . . . 12 (48) . . .
 Aldosterone antagonist . . . 14 (56) . . .
Imaging results
 LV ejection fraction (%) 65 6 3 35 6 10 ,.0001
 LV end diastolic volume (mL) 164 6 31 295 6 123 ,.0001
 LV end diastolic volume indexed body surface area (mL/m2) 87 6 15 145 6 55 ,.0001
 LV end-systolic volume (mL) 56 6 11 200 6 117 ,.0001
 LV stroke volume (mL) 107 6 21 95 6 22 .153
 Cardiac output (L/min) 6.7 6 1.4 5.8 6 1.4 .132
 LV mass (g) 114 6 26 156 6 65 .009
 LV mass indexed body surface area (g/m2) 60 6 10 77 6 28 .013
 LV wall thickness (mm) 8.8 6 1.9 8.7 6 1.5 .862
 Peak circumferential systolic strain (%) 219 6 2 210 6 4 ,.0001
 Peak circumferential diastolic strain rate (sec21) 90 6 7 45 6 22 ,.0001
Note.—Unless otherwise indicated, values are means 6 standard deviation.
* Data are number of patients, with percentage in parentheses.
† For these four patients who were less than 35 years old at the time of diagnosis with no risk factors for coronary disease, a clinical decision was taken not to investigate further because the pretest 
probability was low.
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settings may further improve the quality 
of cardiac 31P MR spectroscopy at 7 T.
Correlations of LV Functional Parameters 
with the PCr/ATP
The 7-T PCr/ATP correlated with LV 
end-diastolic volume (r = 20.59, P 
= .0002), LV end-systolic volume (r = 
20.60, P = .0001), LV ejection fraction 
(r = 0.51, P = .002), peak circumfer-
ential systolic strain (r = 20.44, P = 
.012), and peak diastolic strain rate (r 
= 0.38, P = .034). This suggests that, as 
remodeling parameters and mechanical 
function of the LV deteriorate, so does 
the myocardial energy deficit.
Discussion
All participants imaged at 3 T also suc-
cessfully completed the 7-T sequence, 
demonstrating that cardiac 7-T MR 
imaging and spectroscopy is well toler-
ated by patients. Cardiac 31P MR spec-
troscopy showed a 2.5 times increase 
in SNR at 7 T compared with our best 
methods at 3 T. The PCr/ATP was sim-
ilar at both field strengths, excluding 
any new bias at 7 T. The Cramér-Rao 
lower bounds (measuring uncertainty) 
of PCr/ATP showed a 2.2 times im-
provement at 7 T.
The higher SNR at 7 T can be used 
(a) to obtain higher SNR spectra, (b) 
to increase spatial resolution (eg, for 
of significant LV dysfunction on exertion 
but remained clinically compensated at 
rest, supported by a normal resting car-
diac output (5.8 L/min 6 1.4).
31P MR Spectroscopic Results
Table 2 summarizes the quantitative 
31P MR spectroscopic results. As ex-
pected, there was no significant differ-
ence in the PCr/ATP at 7 T and at 3 T 
(1.54 6 0.39 vs 1.48 6 0.44, P = .49) 
for patients with DCM, as shown in 
Figure 1, A, and the 7-T PCr/ATP for 
the control subjects (1.95 6 0.25) was 
within the accepted range (24). As 
demonstrated in previous lower-field-
strength studies (6,7,25) the PCr/ATP 
was significantly lower, by 21%, in pa-
tients with DCM than in control sub-
jects (1.54 6 0.39 vs 1.95 6 0.25, P = 
.005) at 7 T.
Typical spectra for a patient with 
DCM (Fig 2) show the increased SNR 
at 7 T. The SNR for PCr was 2.5 times 
higher at 7-T field strength than at 3 T. 
Cramér-Rao lower bounds were 45% 
lower at 7 T than at 3 T, showing that 
the higher quality spectra obtained at 7 
T enable more precise metabolite quan-
tification (Fig 1b). Note, however, that 
the mean PCr linewidth was higher at 
7 T (36 Hz) than at 3 T (10 Hz). The 
2.5 times higher SNR in spite of this 
increase in linewidth (Fig 1c) suggests 
that using optimized per-subject B0 shim 
less than .05 were considered to indi-
cate a significant difference.
Results
Participant Characteristics
Demographic, clinical, and imaging data 
are shown in Table 1. Although 72% 
of patients were taking b blockers and 
92% were taking angiotensin converting 
enzyme inhibitors or angiotensin II re-
ceptor blockers, there was no significant 
difference in heart rate or blood pres-
sure compared with control subjects. As 
expected, the mean LV ejection fraction 
was significantly lower in patients with 
DCM than in control subjects (35% 6 
10 vs 65% 6 3, P , .0001), and patients 
with DCM had significantly increased 
end-diastolic volumes compared with 
control subjects (295 mL 6 123 vs 164 
mL 6 31, P , .0001). The peak circum-
ferential systolic strain was significantly 
impaired in patients compared with 
control subjects (210% 6 4 vs 219% 
6 2, P , .0001) as was the peak dia-
stolic strain rate (45 sec21 6 22 vs 90 
sec21 6 7, P , .0001). Patients with 
DCM had higher blood brain-type na-
triuretic peptide levels and achieved sig-
nificantly shorter distances on the 6-mi-
nute walk test than did control subjects 
(see Table 1). Hence the patients with 
DCM recruited to this study had signs 
Table 2
Comparison of Cardiac 31P Spectra Recorded in 25 Patients with DCM at 3 T and 7 T and 10 Healthy Control Subjects at 7 T
Variable
Patients with DCM (n = 25)
Healthy Control  
Subjects (n = 10)
3 T 7 T 7-T to 3-T Ratio P Value 7 T P Value*
PCr SNR 6.5 6 2.4 16.4 6 7.6 2.52 ,.0001 20.2 6 7.0 .1622
PCr amplitude coefficient of variation (%) 17.5 6 6.5 7.1 6 3.7 0.41 ,.0001 5.3 6 2.2 .1713
Linewidth (Hz) 10 6 3 36 6 17 3.60 ,.0001 46 6 22 .1131
Linewidth (ppm) 0.19 6 0.06 0.30 6 0.14 1.58 .0039 0.38 6 0.18 .1115
Flip angle (degrees) 31 6 3 30 6 4 0.97 .4565 30 6 4 .6346
PCr SNR extrapolated to 90° flip angle, TR much greater 
than T1
18.8 6 6.9 43.8 6 19.2 2.33 ,.0001 55.6 6 20.5 .1161
Blood- and saturation-corrected PCr/ATP 1.48 6 0.44 1.54 6 0.39 1.04 .4945 1.95 6 0.25 ,.0001
Mean Cramér-Rao lower bounds on PCr/ATP (%) 32 6 10 18 6 7 0.55 ,.0001 15 6 6 .4129
Note.—Values are means 6 standard deviation, unless otherwise indicated. ppm = parts per million, TR = repetition time, T1 = longitudinal (spin-lattice) relaxation time.
* Comparison of control subjects with patients with DCM at 7 T.
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Figure 1
Figure 1: A, Graph shows PCR/ATP for each patient with 
DCM (mean age, 54 years 6 12; 68% men; further details 
in Table 1) at 3 T compared with that at 7 T. B, Graph shows 
Cramér-Rao lower bounds for each patient with DCM at 3 T 
compared with that at 7 T. C, Graph shows linewidth for PCr 
in hertz at 3 T compared with that at 7 T for each patient with 
DCM. Error bars at sides mark mean and standard deviation. 
In center, each connected pair of points shows data for one 
patient.
investigating regional differences), or (c) 
to decrease the acquisition time (eg, to 
allow dynamic studies under more acute 
stress conditions than could be tolerated 
for a full 28-minute protocol). The in-
creased precision (ie, decreased Cra-
mér-Rao lower bounds) of PCr/ATP also 
may aid separation of subject groups, ei-
ther providing greater confidence in the 
difference between two groups or allow-
ing the identification of smaller between-
group differences.
As found in previous studies at 
lower field strengths, at 7 T the PCr/ATP 
of patients with DCM was significantly 
lower than that of control subjects 
(6,7,25). Although we did not acquire 
control data at 3 T for this study, previ-
ous work by our group has shown aver-
age PCr/ATP in healthy control subjects 
to be 2.07 6 0.38 (5), which would 
be significantly higher than the 3-T 
PCr/ATP of 1.48 6 0.44 in our patients 
with DCM and which would be compa-
rable to that of our 7-T control group 
(P = .37). Our 7-T results are also con-
sistent with findings from lower-field 31P 
MR spectroscopic studies (6), showing 
that the PCr/ATP correlates with the LV 
ejection fraction. We further observed 
that the correlations with the PCr/ATP 
extended also to other markers of LV 
remodeling such as LV end-diastolic 
volume and LV end-systolic volume 
and more subtle earlier markers of 
LV dysfunction such as impaired peak 
systolic strain and impaired diastolic 
strain rates. These findings suggest that 
the increased precision of measuring 
PCr/ATP at 7 T might improve the 
ability of phosphorus spectroscopy to 
deliver biochemical insights through 
comparison with other important car-
diac parameters in future studies.
The mean 6 standard deviation 
of PCr/ATP in control subjects here 
was 1.95 6 0.25 (7 T, control sub-
jects, 16-element coil), which we can 
compare with 2.08 6 0.33 (7 T, con-
trol subjects, 10 cm coil [8]) with 1.71 
6 0.48 (3 T, control subjects, 10 cm 
coil [8]) and with 2.07 6 0.38 (3 T, 
control subjects, heart-liver coil, aver-
age of three voxels [5]). The standard 
deviation of the PCr/ATP decreases 
with increased field strength and with 
more sophisticated radiofrequency 
coils. This is consistent with increased 
measurement precision where the mea-
surement precision is less than the bio-
logic variability.
However, in patients with DCM, 
we observed only a slight reduction in 
the standard deviation of the PCr/ATP 
(1.48 6 0.44 at 3 T vs 1.54 6 0.39 at 
7 T, F test P = .18). This suggests that 
the true biologic variability of PCr/ATP 
in patients with DCM might be greater 
than that in healthy volunteers and of 
a magnitude sufficient to contribute 
substantially to the observed scatter 
at 7 T. Authors of other studies have 
reported an increase in the standard 
deviation of the PCr/ATP in patients 
with DCM (1.41 6 0.12) compared 
with control subjects (1.80 6 0.06 
[26]) and in those with severe DCM 
(1.44 6 0.52) compared with con-
trol subjects (1.95 6 0.45 [7]) and 
of the mean PCr concentration in pa-
tients with heart failure (8.3 6 2.6) 
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groups have made similar observations 
(3,29).
The increased linewidth at 7 T rela-
tive to 3 T is likely due to the increased 
effect of different tissue magnetic sus-
ceptibilities at the higher field strengths 
(eg, at the heart-lung interface); opti-
mized per-subject B0 shimming should 
be able to mitigate this effect in the fu-
ture. Per-subject B0 shimming requires 
1H imaging throughout the chest to 
measure B0 maps, followed by a shim 
current calculation and then cardiac 31P 
MR spectroscopy in the same sequence. 
This is possible and can give an approx-
imately 20% decrease in the PCr line-
width, but only with sophisticated hard-
ware (30).
In comparison to our previous work 
using a 10-cm loop radiofrequency coil, 
the 28 3 30 cm2 transmit loop in the 
16-element array coil (11) provided a 
more uniform excitation across the 
heart, but with a corresponding reduc-
tion in the peak B1
+. This meant that we 
could not reliably excite b-ATP in this 
study, whereas it was straightforward 
with no statistically significant change 
in SNR in the interventricular septum 
(actually a 6% loss in SNR) compared 
with that with the use of the heart-liver 
coil (12). In practice, the differences in 
SNR between coils optimized for cardiac 
applications at 3 T are typically 10%, 
which is much smaller than the gains 
due to increasing field strength from 3 T 
to 7 T (2.5 times increase in SNR).
In this comparison, we chose to 
match flip angles at 30° in the inter-
ventricular septum at both 3 T and 7 
T. This is slightly lower than the Ernst 
flip angle at both field strengths. By 
using T1 values from the literature (8) 
for 31P-containing metabolites, one can 
compute that this choice of flip angle ac-
counts for approximately 8% of the PCr 
SNR gain at 7 T.
Limitations
Individual-subject 7-T to 3-T PCr SNR 
ratios ranged from 0.68 to 6.56; this 
likely reflects differences in the coil-
to-septum distance and in the loading 
of the two coils at 3 T and 7 T. Other 
compared with control subjects (10.1 
6 1.3 [27]). Determining whether 
this is a real effect will require fu-
ture studies, but if it is confirmed, 
then 7-T 31P MR spectroscopy could 
offer an enhanced ability to resolve 
disease-related variations in PCr/ATP 
among patients and could allow better 
resolution to changes in response to 
therapy.
For this comparison, we chose to 
compare our most widely used 3-T coil 
(a heart-liver loop-butterfly coil with 
hardware quadrature combination, Sie-
mens product for 1.5 T, retuned for 3 T) 
with our best available 7-T coil (a 16-ele-
ment receive array used with a software 
combination and the whitened singular 
value decomposition algorithm [28]). 
The improvement seen here reflects re-
al-world improvement at 7 T compared 
with 3 T. This is due both to the increase 
in field strength and to the optimized 
coil at 7 T. However, we note that when 
we previously attempted to introduce 
receive array coils at 3 T, we saw an in-
crease in field of view for the coil, but 
Figure 2
Figure 2: A, Graph shows comparison of spectra in a typical patient (57-year-old woman) at 3 T and 7 T. These spectra have had a matched 
filter applied and have been normalized to mean baseline noise, so the PCr peak height is, by definition, the PCr SNR. Increase in SNR at 7 T is 
readily apparent. B, Corresponding mid-short axis localizer image acquired at 7 T. C, Corresponding four-chamber localizer image acquired at 7 
T. The spectrocopy matrix is overlaid in red, and the voxel plotted in A is highlighted. The yellow-shaded region denotes the regional saturation 
slab used to suppress signal from overlying skeletal muscle.
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